| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Walter Fiers | Q2068397 |
| Xavier Saelens | Q8043303 | ||
| Michael Schotsaert | Q58209646 | ||
| Kenny Roose | Q61129766 | ||
| Bert Schepens | Q96341202 | ||
| P2093 | author name string | Ashley Birkett | |
| Marina De Filette | |||
| Karim El Bakkouri | |||
| P2860 | cites work | Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity | Q47725631 |
| The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection | Q49105055 | ||
| Universal influenza A vaccine: optimization of M2-based constructs | Q49115229 | ||
| Influenza | Q54079365 | ||
| The influence of antigen organization on B cell responsiveness | Q72628042 | ||
| Structure and mechanism of the M2 proton channel of influenza A virus | Q24625464 | ||
| Structural basis for the function and inhibition of an influenza virus proton channel | Q27649742 | ||
| Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins | Q28646344 | ||
| Modified M2 proteins produce heterotypic immunity against influenza A virus. | Q30322254 | ||
| Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. | Q30350403 | ||
| Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. | Q30363500 | ||
| A universal influenza A vaccine based on the extracellular domain of the M2 protein | Q33875466 | ||
| Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse | Q36345130 | ||
| Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins | Q36798311 | ||
| Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. | Q40200090 | ||
| The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues | Q40488169 | ||
| N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. | Q40665104 | ||
| Antibody response to the M2 protein of influenza A virus expressed in insect cells | Q42070575 | ||
| Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface | Q43551346 | ||
| Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys | Q45604167 | ||
| Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. | Q45723623 | ||
| Complete structure of A/duck/Ukraine/63 influenza hemagglutinin gene: animal virus as progenitor of human H3 Hong Kong 1968 influenza hemagglutinin | Q45805493 | ||
| P433 | issue | 45 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| P304 | page(s) | 6280-6283 | |
| P577 | publication date | 2009-10-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | M2e-based universal influenza A vaccine | |
| P478 | volume | 27 |
| Q40911284 | 6-(4-Amino-2-butyl-imidazoquinolyl)-norleucine: Toll-like receptor 7 and 8 agonist amino acid for self-adjuvanting peptide vaccine |
| Q41180799 | A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate |
| Q45354359 | A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles. |
| Q30401712 | A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus |
| Q37547653 | A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2. |
| Q30387700 | A universal long-term flu vaccine may not prevent severe epidemics |
| Q34019854 | AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection |
| Q30370445 | Adenoviral vectors as novel vaccines for influenza. |
| Q27010100 | Advancements in the development of subunit influenza vaccines |
| Q38285425 | Advances and challenges in the development and production of effective plant-based influenza vaccines |
| Q30364315 | Advances in influenza vaccination. |
| Q40076766 | An Adenovirus-Vectored Influenza Vaccine Induces Durable Cross-Protective Hemagglutinin Stalk Antibody Responses in Mice |
| Q90194712 | An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains |
| Q36675921 | An Influenza Virus M2 Protein Specific Chimeric Antigen Receptor Modulates Influenza A/WSN/33 H1N1 Infection In Vivo |
| Q92997269 | An amphiphilic invertible polymer as a delivery vehicle for a M2e-HA2-HA1 peptide vaccine against an Influenza A virus in pigs |
| Q30383623 | Animal models for the preclinical evaluation of candidate influenza vaccines. |
| Q37900305 | Animal models to assess the toxicity, immunogenicity and effectiveness of candidate influenza vaccines |
| Q38285854 | Antigen delivery by virus-like particles for immunotherapeutic vaccination. |
| Q34416393 | Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity |
| Q40280642 | Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2. |
| Q40158436 | Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus |
| Q40730765 | Controlling influenza by cytotoxic T-cells: calling for help from destroyers |
| Q30430152 | Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. |
| Q30396399 | Cross-protective immunity to influenza A viruses |
| Q26783897 | Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head |
| Q58199835 | Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective e |
| Q38510148 | Development of cross-protective influenza a vaccines based on cellular responses |
| Q84223258 | Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e |
| Q30355116 | Development of universal influenza vaccines based on influenza virus M and NP genes. |
| Q37951525 | Developments in virus-like particle-based vaccines for infectious diseases and cancer |
| Q38618258 | Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems |
| Q91907997 | Effect of vaccination strategies on the dynamic behavior of epidemic spreading and vaccine coverage |
| Q41606678 | Effective degree Markov-chain approach for discrete-time epidemic processes on uncorrelated networks. |
| Q47105096 | Efficacy of an Adenoviral Vectored Multivalent Centralized Influenza Vaccine. |
| Q40917826 | Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine |
| Q45076219 | Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin |
| Q36065047 | Epitope Mapping of Avian Influenza M2e Protein: Different Species Recognise Various Epitopes |
| Q47132009 | Escherichia coli-derived virus-like particles in vaccine development |
| Q41685260 | Evaluation of nanoparticle tracking analysis for total virus particle determination |
| Q38061423 | Evasion of influenza A viruses from innate and adaptive immune responses. |
| Q40961165 | Generation of New M2e-HA2 Fusion Chimeric Peptide to Development of a Recombinant Fusion Protein Vaccine. |
| Q64374871 | Genetic control of immune responses to influenza A matrix 2 protein (M2) |
| Q38081969 | Hepatitis B core-based virus-like particles to present heterologous epitopes |
| Q40165332 | High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin. |
| Q39396533 | High-level systemic expression of conserved influenza epitope in plants on the surface of rod-shaped chimeric particles |
| Q40043323 | Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection |
| Q30227201 | Historical review of pandemic influenza A in Taiwan, 2009. |
| Q27341132 | Identification of a novel splice variant form of the influenza A virus M2 ion channel with an antigenically distinct ectodomain |
| Q42233708 | Immune responses to oral and IM administration of M2e-Hsp70 construct. |
| Q34430020 | Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge |
| Q30416980 | In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine |
| Q30413095 | Induction of a cross-reactive antibody response to influenza virus M2 antigen in pigs by using a Sendai virus vector |
| Q55096280 | Influence of the Linking Order of Fragments of HA2 and M2e of the influenza A Virus to Flagellin on the Properties of Recombinant Proteins. |
| Q30396318 | Influenza A viruses: why focusing on M2e-based universal vaccines |
| Q38160083 | Influenza vaccines: from whole virus preparations to recombinant protein technology |
| Q37748492 | Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses |
| Q37570525 | Inter-Clade Protection Offered by Mw-Adjuvanted Recombinant HA, NP Proteins, and M2e Peptide Combination Vaccine in Mice Correlates with Cellular Immune Response |
| Q34059627 | Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice |
| Q34070683 | Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge |
| Q90115273 | Intranasally administered protein coated chitosan nanoparticles encapsulating influenza H9N2 HA2 and M2e mRNA molecules elicit protective immunity against avian influenza viruses in chickens |
| Q26783493 | M2e-Based Universal Influenza A Vaccines |
| Q40291797 | M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection. |
| Q30358935 | MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses |
| Q38465267 | Nasal and pulmonary vaccine delivery using particulate carriers |
| Q38009579 | New technologies for new influenza vaccines. |
| Q35165017 | Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner. |
| Q52599675 | Novel Platforms for the Development of a Universal Influenza Vaccine. |
| Q34102290 | Options and obstacles for designing a universal influenza vaccine |
| Q91639170 | Plant Viruses in Plant Molecular Pharming: Toward the Use of Enveloped Viruses |
| Q89511342 | Plant-Produced Recombinant Influenza A Virus Candidate Vaccine Based on Flagellin Linked to Conservative Fragments of M2 Protein and Hemagglutintin |
| Q36888029 | Plant-derived virus-like particles as vaccines |
| Q30373993 | Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles. |
| Q40110283 | Promising approaches for the treatment and prevention of viral respiratory illnesses |
| Q38580454 | Prospects for broadly protective influenza vaccines |
| Q30407650 | Prospects for controlling future pandemics of influenza |
| Q30401519 | Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin |
| Q35209148 | Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin |
| Q35656657 | Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice. |
| Q90043367 | Protective immunity against influenza virus challenge by norovirus P particle-M2e and HA2-AtCYN vaccines in chickens |
| Q35645628 | Rapid high-yield expression of a candidate influenza vaccine based on the ectodomain of M2 protein linked to flagellin in plants using viral vectors |
| Q57093970 | Reduction of influenza virus transmission from mice immunized against conserved viral antigens is influenced by route of immunization and choice of vaccine antigen |
| Q44197848 | Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24-26 January 2013. |
| Q36402952 | Subtype- and antigenic site-specific differences in biophysical influences on evolution of influenza virus hemagglutinin |
| Q33812653 | Subviral particle as vaccine and vaccine platform |
| Q36267431 | Supplementation of inactivated influenza vaccine with norovirus P particle-M2e chimeric vaccine enhances protection against heterologous virus challenge in chickens. |
| Q42240514 | Supplementation of oil-based inactivated H9N2 vaccine with M2e antigen enhances resistance against heterologous H9N2 avian influenza virus infection |
| Q30402300 | Swine-origin influenza-virus-induced acute lung injury: Novel or classical pathogenesis? |
| Q89967522 | Synthesis and Assembly of Hepatitis B Virus-Like Particles in a Pichia pastoris Cell-Free System |
| Q30373251 | Synthesis and Immunogenicity Assessment of Elastin-Like Polypeptide-M2e Construct as an Influenza Antigen. |
| Q38931638 | Synthesis and characterization of antigenic influenza A M2e protein peptide-poly(acrylic) acid bioconjugate and determination of toxicity in vitro |
| Q92905919 | Targeting M2e to DEC-205 induces an enhanced serum antibody-dependent heterosubtypic protection against influenza A virus infection |
| Q50453718 | The evolution of seasonal influenza viruses |
| Q35661358 | The potential economic value of a 'universal' (multi-year) influenza vaccine |
| Q27003874 | Towards a universal influenza vaccine: volunteer virus challenge studies in quarantine to speed the development and subsequent licensing |
| Q36950550 | Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins |
| Q36436730 | Turning self-destructing Salmonella into a universal DNA vaccine delivery platform |
| Q30361950 | Universal influenza vaccines, a dream to be realized soon. |
| Q30392373 | Universal vaccines: shifting to one for many |
| Q37919551 | Universal vaccines: shifting to one for many or shooting too high too soon! |
| Q38643466 | Use of computational and recombinant technologies for developing novel influenza vaccines |
| Q41811188 | Vaccination induced antibodies to recombinant avian influenza A virus M2 protein or synthetic M2e peptide do not bind to the M2 protein on the virus or virus infected cells. |
| Q34105207 | Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice |
| Q45369861 | Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens |
| Q38832835 | Vaccines: could asthma in young children be a preventable disease? . |
| Q58476143 | Virus-Like Particle Bioprocessing |
| Q38059059 | Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development |
| Q40263422 | Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice |
| Q37798008 | Virus-like particles in vaccine development. |
| Q38088523 | Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development |
| Q90014164 | Why are vaccines against many human viral diseases still unavailable; an historic perspective? |
Search more.